JPS6225646B2 - - Google Patents

Info

Publication number
JPS6225646B2
JPS6225646B2 JP54147896A JP14789679A JPS6225646B2 JP S6225646 B2 JPS6225646 B2 JP S6225646B2 JP 54147896 A JP54147896 A JP 54147896A JP 14789679 A JP14789679 A JP 14789679A JP S6225646 B2 JPS6225646 B2 JP S6225646B2
Authority
JP
Japan
Prior art keywords
adjuvant
antigen
compound
red blood
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP54147896A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5671024A (en
Inventor
Shiiraa Uorufu Za Saado Jon
Robaato Hemuzuwaasu Jooji
Edoin Jensen Keisu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Original Assignee
PFIZER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER filed Critical PFIZER
Publication of JPS5671024A publication Critical patent/JPS5671024A/ja
Publication of JPS6225646B2 publication Critical patent/JPS6225646B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP14789679A 1979-10-26 1979-11-13 Vaccine adjuvant Granted JPS5671024A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/088,638 US4310550A (en) 1979-10-26 1979-10-26 Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants

Publications (2)

Publication Number Publication Date
JPS5671024A JPS5671024A (en) 1981-06-13
JPS6225646B2 true JPS6225646B2 (enExample) 1987-06-04

Family

ID=22212534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP14789679A Granted JPS5671024A (en) 1979-10-26 1979-11-13 Vaccine adjuvant

Country Status (7)

Country Link
US (1) US4310550A (enExample)
JP (1) JPS5671024A (enExample)
AU (1) AU522338B2 (enExample)
CA (1) CA1163562A (enExample)
DE (1) DE2945788A1 (enExample)
NZ (1) NZ195354A (enExample)
PT (1) PT71236A (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058021A3 (en) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmaceutical compositions
IL74289A (en) * 1985-02-10 1989-02-28 Israel State Vaccine system comprising a live-non-virulent vaccine and an adjuvant
NL9000207A (enExample) * 1990-01-29 1991-08-16 Duphar Int Res
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
AU2002218927B2 (en) 2001-01-04 2007-08-30 The University Of British Columbia Enterohemorrhagic Escherichia coli vaccine
MXPA06004858A (es) 2003-10-31 2007-04-16 Univ British Columbia Factores de virulencia bacteriana y sus usos.
KR20110132416A (ko) 2004-04-05 2011-12-07 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
US20080102067A1 (en) * 2006-10-25 2008-05-01 Cook Mark E Immunogenic composition
US20190030153A1 (en) 2015-07-22 2019-01-31 University Of Saskatchewan Mycoplasma vaccines and uses thereof
EP4138894A4 (en) 2020-04-20 2024-06-26 The University of Saskatchewan COMPOSITIONS AND METHODS FOR THE PREVENTION, CONTROL AND DIAGNOSIS OF MYCOBACTERIAL INFECTIONS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) * 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US3872171A (en) * 1971-05-24 1975-03-18 Pfizer Polyamines as antiviral agents in animals
US4034040A (en) * 1971-05-24 1977-07-05 Pfizer Inc. Xylene-diamines as antiviral agents
US4173641A (en) * 1978-05-15 1979-11-06 Pfizer Inc. Di-O-n-alkyl glycerol derivatives as immune stimulants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEWER ASPECTS OF IMMUNOLOGY WITH THERAPEUTIC PROSPECTS=1979 *

Also Published As

Publication number Publication date
US4310550A (en) 1982-01-12
NZ195354A (en) 1982-12-21
CA1163562A (en) 1984-03-13
AU6366480A (en) 1981-04-30
PT71236A (en) 1980-06-01
DE2945788A1 (de) 1981-05-07
JPS5671024A (en) 1981-06-13
AU522338B2 (en) 1982-05-27
DE2945788C2 (enExample) 1988-01-28

Similar Documents

Publication Publication Date Title
JP4743928B2 (ja) 処方物
JP2648305B2 (ja) 多糖類ワクチン
JP2515321B2 (ja) ワクチン処方
JPH041728B2 (enExample)
JP2010265330A6 (ja) 処方物
HU228384B1 (en) Vaccine compositions
US10702595B2 (en) Manufacture of vaccines and compositions for the prevention of Salmonella infections
BRPI0412444B1 (pt) fração de quil a com baixa toxidez e seu uso
JPH08325163A (ja) 哺乳動物用ワクチン組成物
US4395394A (en) Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
JP2003519669A (ja) 舌下投与用の抗原および糖脂質アジュバントの組成物
JP2756321B2 (ja) 水酸化亜鉛または水酸化鉄をアジュバントとして含有する抗原溶液
JP2012140456A (ja) 髄膜炎菌由来の誘導体化多糖類−タンパク質の多価コンジュゲートおよびワクチン
US4310550A (en) Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
PT98119B (pt) Processo para a preparacao de adjuvantes para vacinas aperfeicoados compreendendo lipopolissacarideos nao toxicos e/ou copolimeros de polioxietileno-polioxipropileno
US6528058B1 (en) Saponin adjuvant composition
JPH07503238A (ja) コレラ予防用の無毒化ｌｐｓ−コレラ毒素結合ワクチン
JP4889175B2 (ja) 感染性因子に対する免疫応答を刺激するための組成物および方法
US6905712B2 (en) Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
US4172125A (en) Oil-free adjuvant compositions containing N-acetyl-muramyl-L-alanyl-D-glutamic acid and method of use
RU2021816C1 (ru) Способ получения вакцины против холеры
CN113663066B (zh) 一种肌醇阿拉伯甘露寡糖缀合物及在抗结核疫苗中的应用
CA2525615C (en) Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine
WO1986004243A1 (en) Method & product for enhancing circulating antibody response
AU2003268581B2 (en) Formulation